Literature DB >> 8989923

Alpha-fetoprotein as a TNF resistance factor for the human hepatocarcinoma cell line HepG2.

L N Semenkova1, E I Dudich, I V Dudich, L N Shingarova, V G Korobko.   

Abstract

Human hepatocarcinoma HepG2 cells are known to be insensitive to tumor necrosis factor (TNF) cytotoxicity. In this report, preliminary washing of HepG2 cells with serum-free medium to remove endogenous and exogenous alpha-fetoprotein (AFP) from the cultivation medium transfers cells from the TNF-resistant to the TNF-sensitive state without addition of any transcriptional inhibitors. HepG2 cells sensitized to by washing again became TNF-resistant after their treatment with exogenous AFP. Protective AFP activity against TNF-induced cytotoxicity directly depends on the AFP/TNF concentration ratio, demonstrating biphasic AFP activity. Our data show that 0.2 mg/ml of AFP acts synergistically to enhance cytotoxicity of suboptimal TNF doses. In contrast, the same AFP dose significantly attenuates the cytotoxicity of high TNF doses. It is concluded that AFP can function as a protective factor against TNF cytotoxicity in human hepatoma cells. These observations suggest that AFP secretion by certain tumor cells allows a highly flexible regulation of TNF cytotoxicity, dependent on the amount of endogenous AFP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8989923     DOI: 10.1159/000218013

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  10 in total

1.  An additional long-term mechanism of NF-κB regulation after cytokine treatment in a human hepatoma cell line.

Authors:  Patricia Kohlhof
Journal:  Virchows Arch       Date:  2010-09-23       Impact factor: 4.064

2.  In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by taxol.

Authors:  V G Minero; D De Stefanis; P Costelli; F M Baccino; G Bonelli
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.

Authors:  Viktoria N Evdokimova; Yang Liu; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunother       Date:  2007 May-Jun       Impact factor: 4.456

4.  alpha-Fetoprotein as a modulator of the pro-inflammatory response of human keratinocytes.

Authors:  A I Potapovich; S Pastore; V A Kostyuk; D Lulli; V Mariani; C De Luca; E I Dudich; L G Korkina
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

5.  Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer.

Authors:  Lu Zheng; Wei Gong; Ping Liang; XiaoBing Huang; Nan You; Ke Qiang Han; Yu Ming Li; Jing Li
Journal:  Tumour Biol       Date:  2014-01-15

6.  Liver cell line derived conditioned medium enhances myofibril organization of primary rat cardiomyocytes.

Authors:  Jinseok Kim; Yu-Shik Hwang; Alice Mira Chung; Bong Geun Chung; Ali Khademhosseini
Journal:  Mol Cells       Date:  2012-07-25       Impact factor: 5.034

Review 7.  Alpha-fetoprotein: a renaissance.

Authors:  A A Terentiev; N T Moldogazieva
Journal:  Tumour Biol       Date:  2013-06-14

8.  Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB.

Authors:  Michael Biermer; Robyn Puro; Robert J Schneider
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Intracellular alpha-fetoprotein mitigates hepatocyte apoptosis and necroptosis by inhibiting endoplasmic reticulum stress.

Authors:  Yun-Fen Chen; Si-Ying Liu; Qi-Jiao Cheng; Yu-Jiao Wang; Shuang Chen; Yi-Yang Zhou; Xia Liu; Zhi-Gang Jiang; Wei-Wei Zhong; Yi-Huai He
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

Review 10.  Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives.

Authors:  Maria Pallozzi; Natalia Di Tommaso; Valeria Maccauro; Francesco Santopaolo; Antonio Gasbarrini; Francesca Romana Ponziani; Maurizio Pompili
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.